In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473

British Journal of Cancer

Volumn 77, Issue 3, 1998, Pages 366-373

  Holford, J ^a   Sharp, S Y ^a   Murrer, B A ^b   Abrams, M ^c   Kelland, L R ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b JOHNSON MATTHEY TECHNOLOGY CENTRE   (United Kingdom)

^c GENZYME CORPORATION   (United States)

Author keywords

AMD473; Circumvention; Ovarian carcinoma; Platinum; Resistance

Indexed keywords

CARBOPLATIN; CIS AMMINEDICHLORO(2 METHYLPYRIDINE) PLATINUM(II); CISPLATIN; GLUTATHIONE; PLATINUM COMPLEX; PROTEIN P53; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL LEVEL; CELL SURVIVAL; CLONOGENIC ASSAY; CONTROLLED STUDY; CROSS LINKING; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG DNA BINDING; DRUG POTENCY; DRUG RESISTANCE; DRUG STRUCTURE; GENE INDUCTION; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL; STEREOSPECIFICITY;

EID: 0031962973     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.59     Document Type: Article

References (41)

1. Behrens BC, Hamilton TC, Masuda H, Grotzinger KR, Whang-Peng J, Louie KG, Knutsen T, McKoy WM, Young RC and Ozols RF (1987) Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian carcinoma cell line and its use in evaluation of platinum analogs. Cancer Res 47: 414-418
2. Burchenal JH, Kalaher K, Dew K and Lokys L (1979) Rationale for development of platinum analogs. Cancer Treat Rep 63: 1493-1498
3. Calsou P and Salles B (1993) Role of DNA repair in the mechanism of cell resistance to alkylating agents and cisplatin. Cancer Chemother Pharmacol 32: 85-89
4. Canetta R, Rozencweig M, Wittes RE and Schacter LP (1990) Platinum coordination complexes in cancer chemotherapy: an historical perspective. Cancer Chemotherapy:. Challenges for the Future 5: 318-323
5. Delmastro DA, Li J, Vaisman A, Solle M and Chancy SG (1997) DNA damage-inducible gene expression following platinum treatment in human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 39: 245-253
6. Gately DP and Howell SB (1993) Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer 67: 1171-1176
7. Goddard P, Orr RM, Valenti MR, Barnard CFJ, Murrer BA, Kelland LR and Harrap, KR (1996) Novel trans platinum complexes: comparative in vitro and in vivo activity against platinum-sensitive and -resistant murine tumours. Anticancer Res 16: 33-38
8. Harrap KR (1985) Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treat Rev 12(suppl. A): 21-33
9. Hills CA, Kelland LR, Abel G, Siracky J, Wilson AP and Harrap KR (1989) Biological properties often human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. Br J Cancer 59: 527-314
10. Hedley DW and Chow S (1994) Evaluation of methods for measuring cellular glutathione content using flow cytometry. Cytometry 15: 349-358
11. Holford J, Sharp SY, Murrer BA and Kelland LR (1996) In vitro evaluation of JM473, a novel sterically hindered platinum(II) complex abstract 122. Anal Oncol 7 (suppl. 1): 37
12. Holford J, Raynaud F, Murrer BA, Grimaldi K, Hartley JA, Abrams M and Kelland LR (1997) Chemical, biochemical and pharmacological activity of the novel sterically hindered platinum co-ordination complex cis-[amminedichloro(2-methylpyridine)]platinum (II)( AM0473). Anti-Cancer Drug Design (in press)
13. Ishikawa T, Wright CD and Ishizuka H (1994) GS-X pump is functionally overexpressed in cis-diamminedichloroplatinum(II)-resistant human leukemia HL-60 cells and down-regulated by cell differentiation. J Biol Chem 269: 29085-29093
14. Johnson SW, Perez RP, Godwin AK, Yeung AT, Handel LM, Ozols RF and Hamilton TC (1994) Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines. Biochem Pharmacol 47: 689-697
15. Kasahara K, Fujiwara Y, Nishio K, Ohmori T, Sugimoto Y, Komiya K, Matsuda T and Saijo N (1991) Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. Cancer Res 51: 3237-3242
16. Kelland LR (1993) New platinum antitumor complexes. Crit Rev Oncol/Hematol 15: 191-219
17. Kelland LR, Murrer BA, Abel G, Giandomenico CM, Mistry P and Harrap KR (1992a) Ammine/amine platinum (IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian cell lines. Cancer Res 52: 822-828
18. Kelland LR, Mistry P, Abel G, Loh SY, O'Neill CF, Murrer BA and Harrap KR (1992b) Mechanism-related circumvention of cis-diamminedichloroplatinum(II) acquired resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates. Cancer Res 52: 3857-3864
19. Kelland LR, Abel G, McKeage MJ, Jones M, Goddard PM, Valenti M, Murrer BA and Harrap KR (1993) Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum (IV): an orally active platinum drug. Cancer Res 53: 2581-2586
20. Kelland LR, Barnard CFJ, Mellish KJ, Jones M, Goddard PM, Valenti M, Bryant A, Murrer BA and Harrap KR (1994) A novel trans platinum coordination complex possessing in vitro and in vivo antitumor activity. Cancer Res 54: 5618-5622
21. Kelland LR, Barnard CFJ, Evans IG, Murrer BA, Theobald BRC, Vaughan OJ, Wyer SB, Goddard PM, Jones M, Valenti M, Bryant A, Rogers PM and Harrap KR (1995) Synthesis and in vitro and in vivo antitumor activity of a series of trans platinum antitumor complexes. J Med Chem 38: 3016-3024
22. Kelland LR, Holford J, Hartley JA, Murrer BA and Harrap KR (1996) JM473: a novel sterically hindered platinum (II) complex showing non cross-resistance properties to cisplatin. Proc Am Assoc Cancer Res 37: A2748
23. Kohn KW (1987) DNA filter elution methods in anticancer drug development. Cancer Treat Res 36: 3-38
24. Lai GM, Ozols RF, Young RC and Hamilton TC (1989) Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines. J Natl Cancer Inst 81: 535-539
25. Loehrer P and Einhorn LH (1984) Cisplatin, diagnosis and treatment. Ann Inter Med 10: 704-713
26. Loh SY, Mistry P, Kelland LR, Abel G and Harrap KR (1992) Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes. Br J Cancer 66: 1109-1115
27. Lowry OH, Rosebrough MT, Farr AL and Randall RJ (1951) Protein measurements with the folin phenol reagent. J Biol Chem 193: 265-269
28. Mamenta EL, Poma E, Kaufmann WK, Delmastro DA, Grady HL and Chancy SG (1994) Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian cancer cell lines. Cancer Res 54: 3500-3505
29. Mellish KJ and Kelland LR (1994) Mechanisms of acquired resistance to the orally active platinum-based anticancer drug Bis-acetato-ammine-dichloro-cyclohexylamine Platinum(IV) (JM216) in two human ovarian carcinoma cell lines. Cancer Res 54: 6194-6200
30. Mellish KJ, Barnard CFJ, Murrer BA and Kelland LR (1995) DNA binding properties of novel cis-and trans-platinum-based anticancer agents in 2 human ovarian carcinoma cell lines. Int J Cancer 62: 717-723
31. Miller SA, Dykes DD and Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16: 1215
32. McKeage MJ, Mistry P, Ward J, Boxall FE, Loh S, O'Neill C, Ellis P, Kelland LR, Morgan SE, Murrer BA, Santabarbara P, Harrap KR and Judson IR (1995) Phase I and pharmacological study of an oral platinum complex (JM216): dose dependent pharmacokinetics with single dose administration. Cancer Chemother Pharmacol 36: 451-458
33. Nishimura T, Newkirk K, Sessions RB, Andrews PA, Trock BJ, Rasmussen AA, Montgomery EA, Bischoff EK and Cullen KJ (1996) Immunohistochemical staining for glutathione S-transferase predicts response to platinum-based chemotherapy in head and neck cancer. Clin Cancer Res 2: 1859-1865
34. O'Neill C, Orr RM, Kelland LR and Harrap KR (1995) Comparison of platinum (Pt) binding to DNA, and removal of total Pt adducts and interstrand crosslinks in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin. Cell Pharmacol 2: 1-7
35. Pendyala L, Creaven PJ, Perez R, Zdanowicz JR and Raghavan D (1995) Intracellular glutathione and cytotoxicity of platinum complexes. Cancer Chemother Pharmacol 36: 271-278
36. Sharp SY, Rogers P and Kelland LR (1995) Transport of cisplatin and bis-acetato-ammine dichlorocyclohexylamine platinum(IV) (JM216) in human ovarian carcinoma cell lines: Identification of a plasma membrane protein associated with cisplatin resistance. Clin Cancer Res 1: 981-989
37. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Visitica D, Warren J, Bokesch H, Kennedy S and Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer drug screening. J Natl Cancer Inst 82: 1107-1112
38. Towbin H, Staehelin T and Gordon J (1979) Electrophoresis transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedures and some applications. Proc Natl Acad Sci USA 76: 350-4354
39. Versantvoort CHM, Broxterman HJ, Bagrij T, Scheper RJ and Twentyman PR (1995) Regulation by glutathione of drug transport in multidrug-resistant human lung tumour cell lines overexpressing multidrug resistance-associated protein. Br J Cancer 72: 82-89
40. Walton MI, Koshy P, Wu E and Kelland LR (1995) Molecular characterization of a panel of human ovarian cancers with respect to p53 status and cis-platinum chemosensitivity. In Proceedings of the 7th International Symposium on Platinum and Other Metal Co-ordination Compounds in Cancer Chemotherapy, European Cancer Centre, Amsterdam, March 1-4, abstract 121
41. Yarbo JW (ed) (1992) Carboplatin (JM8) update: current perspectives and future directions. Semin Oncol 19(suppl. 2): 1-164